Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Inflammation and N-formyl peptide receptors mediate the angiogenic activity of human vitreous humour in proliferative diabetic retinopathy.

Rezzola S, Corsini M, Chiodelli P, Cancarini A, Nawaz IM, Coltrini D, Mitola S, Ronca R, Belleri M, Lista L, Rusciano D, De Rosa M, Pavone V, Semeraro F, Presta M.

Diabetologia. 2017 Apr;60(4):719-728. doi: 10.1007/s00125-016-4204-0. Epub 2017 Jan 13.

PMID:
28083635
2.

Endothelial cell dysfunction in globoid cell leukodystrophy.

Belleri M, Presta M.

J Neurosci Res. 2016 Nov;94(11):1359-67. doi: 10.1002/jnr.23744. Epub 2016 Apr 1. Review.

PMID:
27037626
3.

Brain angioarchitecture and intussusceptive microvascular growth in a murine model of Krabbe disease.

Giacomini A, Ackermann M, Belleri M, Coltrini D, Nico B, Ribatti D, Konerding MA, Presta M, Righi M.

Angiogenesis. 2015 Oct;18(4):499-510. doi: 10.1007/s10456-015-9481-6. Epub 2015 Aug 27.

PMID:
26310512
4.

Antiangiogenic Effectiveness of the Urokinase Receptor-Derived Peptide UPARANT in a Model of Oxygen-Induced Retinopathy.

Dal Monte M, Rezzola S, Cammalleri M, Belleri M, Locri F, Morbidelli L, Corsini M, Paganini G, Semeraro F, Cancarini A, Rusciano D, Presta M, Bagnoli P.

Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2392-407. doi: 10.1167/iovs.14-16323.

PMID:
25766585
5.

Therapeutic Potential of Anti-Angiogenic Multitarget N,O-Sulfated E. Coli K5 Polysaccharide in Diabetic Retinopathy.

Rezzola S, Dal Monte M, Belleri M, Bugatti A, Chiodelli P, Corsini M, Cammalleri M, Cancarini A, Morbidelli L, Oreste P, Bagnoli P, Semeraro F, Presta M.

Diabetes. 2015 Jul;64(7):2581-92. doi: 10.2337/db14-1378. Epub 2015 Feb 18.

6.

Molecular cloning and knockdown of galactocerebrosidase in zebrafish: new insights into the pathogenesis of Krabbe's disease.

Zizioli D, Guarienti M, Tobia C, Gariano G, Borsani G, Bresciani R, Ronca R, Giacopuzzi E, Preti A, Gaudenzi G, Belleri M, Di Salle E, Fabrias G, Casas J, Ribatti D, Monti E, Presta M.

Biochim Biophys Acta. 2014 Apr;1842(4):665-75. doi: 10.1016/j.bbadis.2014.01.008. Epub 2014 Jan 24.

7.

In vitro and ex vivo retina angiogenesis assays.

Rezzola S, Belleri M, Gariano G, Ribatti D, Costagliola C, Semeraro F, Presta M.

Angiogenesis. 2014 Jul;17(3):429-42. Review.

PMID:
24121991
8.

Inhibition of angiogenesis by β-galactosylceramidase deficiency in globoid cell leukodystrophy.

Belleri M, Ronca R, Coltrini D, Nico B, Ribatti D, Poliani PL, Giacomini A, Alessi P, Marchesini S, Santos MB, Bongarzone ER, Presta M.

Brain. 2013 Sep;136(Pt 9):2859-75. doi: 10.1093/brain/awt215.

9.

A novel ex vivo murine retina angiogenesis (EMRA) assay.

Rezzola S, Belleri M, Ribatti D, Costagliola C, Presta M, Semeraro F.

Exp Eye Res. 2013 Jul;112:51-6. doi: 10.1016/j.exer.2013.04.014. Epub 2013 Apr 27.

PMID:
23631846
10.

Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer.

Ronca R, Alessi P, Coltrini D, Di Salle E, Giacomini A, Leali D, Corsini M, Belleri M, Tobia C, Garlanda C, Bonomi E, Tardanico R, Vermi W, Presta M.

J Pathol. 2013 Jun;230(2):228-38. doi: 10.1002/path.4181.

PMID:
23424081
11.

Matrigel plug assay: evaluation of the angiogenic response by reverse transcription-quantitative PCR.

Coltrini D, Di Salle E, Ronca R, Belleri M, Testini C, Presta M.

Angiogenesis. 2013 Apr;16(2):469-77. doi: 10.1007/s10456-012-9324-7. Epub 2012 Nov 11.

PMID:
23143707
12.

Anti-angiogenic activity of the flavonoid precursor 4-hydroxychalcone.

Varinska L, van Wijhe M, Belleri M, Mitola S, Perjesi P, Presta M, Koolwijk P, Ivanova L, Mojzis J.

Eur J Pharmacol. 2012 Sep 15;691(1-3):125-33. doi: 10.1016/j.ejphar.2012.06.017. Epub 2012 Jun 18.

PMID:
22721615
13.

Substrate-immobilized HIV-1 Tat drives VEGFR2/α(v)β(3)-integrin complex formation and polarization in endothelial cells.

Urbinati C, Ravelli C, Tanghetti E, Belleri M, Giacopuzzi E, Monti E, Presta M, Rusnati M.

Arterioscler Thromb Vasc Biol. 2012 May;32(5):e25-34. doi: 10.1161/ATVBAHA.111.242396. Epub 2012 Feb 23.

14.

The thymidine phosphorylase inhibitor 5'-O-tritylinosine (KIN59) is an antiangiogenic multitarget fibroblast growth factor-2 antagonist.

Liekens S, Bronckaers A, Belleri M, Bugatti A, Sienaert R, Ribatti D, Nico B, Gigante A, Casanova E, Opdenakker G, Pérez-Pérez MJ, Balzarini J, Presta M.

Mol Cancer Ther. 2012 Apr;11(4):817-29. doi: 10.1158/1535-7163.MCT-11-0738. Epub 2012 Feb 1.

15.

Long pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction: a biological rheostat for fibroblast growth factor 2-mediated angiogenesis.

Leali D, Inforzato A, Ronca R, Bianchi R, Belleri M, Coltrini D, Di Salle E, Sironi M, Norata GD, Bottazzi B, Garlanda C, Day AJ, Presta M.

Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):696-703. doi: 10.1161/ATVBAHA.111.243998. Epub 2012 Jan 19.

16.

The natural compound n-butylidenephthalide derived from the volatile oil of Radix Angelica sinensis inhibits angiogenesis in vitro and in vivo.

Yeh JC, Cindrova-Davies T, Belleri M, Morbidelli L, Miller N, Cho CW, Chan K, Wang YT, Luo GA, Ziche M, Presta M, Charnock-Jones DS, Fan TP.

Angiogenesis. 2011 May;14(2):187-97. doi: 10.1007/s10456-011-9202-8. Epub 2011 Feb 15.

PMID:
21327473
17.

Antiangiogenic activity of a neutralizing human single-chain antibody fragment against fibroblast growth factor receptor 1.

Ronca R, Benzoni P, Leali D, Urbinati C, Belleri M, Corsini M, Alessi P, Coltrini D, Calza S, Presta M, Dell'Era P.

Mol Cancer Ther. 2010 Dec;9(12):3244-53. doi: 10.1158/1535-7163.MCT-10-0417. Epub 2010 Oct 12.

18.

The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo.

Vandercappellen J, Liekens S, Bronckaers A, Noppen S, Ronsse I, Dillen C, Belleri M, Mitola S, Proost P, Presta M, Struyf S, Van Damme J.

Mol Cancer Res. 2010 Mar;8(3):322-34. doi: 10.1158/1541-7786.MCR-09-0176. Epub 2010 Mar 9.

19.

Impact of VEGF-dependent tumour micro-environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice.

Coltrini D, Ronca R, Belleri M, Zardi L, Indraccolo S, Scarlato V, Giavazzi R, Presta M.

J Pathol. 2009 Dec;219(4):455-62. doi: 10.1002/path.2626.

PMID:
19824060
20.

alphavbeta3 Integrin-dependent antiangiogenic activity of resveratrol stereoisomers.

Belleri M, Ribatti D, Savio M, Stivala LA, Forti L, Tanghetti E, Alessi P, Coltrini D, Bugatti A, Mitola S, Nicoli S, Vannini V, Presta M.

Mol Cancer Ther. 2008 Dec;7(12):3761-70. doi: 10.1158/1535-7163.MCT-07-2351.

21.

A pro-inflammatory signature mediates FGF2-induced angiogenesis.

Andrés G, Leali D, Mitola S, Coltrini D, Camozzi M, Corsini M, Belleri M, Hirsch E, Schwendener RA, Christofori G, Alcamí A, Presta M.

J Cell Mol Med. 2009 Aug;13(8B):2083-108. doi: 10.1111/j.1582-4934.2008.00415.x.

22.

Angiopoietin-1 mediates the proangiogenic activity of the bone morphogenic protein antagonist Drm.

Mitola S, Moroni E, Ravelli C, Andres G, Belleri M, Presta M.

Blood. 2008 Aug 15;112(4):1154-7. doi: 10.1182/blood-2007-09-111450. Epub 2008 May 27.

23.

Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor.

Stabile H, Mitola S, Moroni E, Belleri M, Nicoli S, Coltrini D, Peri F, Pessi A, Orsatti L, Talamo F, Castronovo V, Waltregny D, Cotelli F, Ribatti D, Presta M.

Blood. 2007 Mar 1;109(5):1834-40. Epub 2006 Oct 31.

24.

Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine.

Mitola S, Belleri M, Urbinati C, Coltrini D, Sparatore B, Pedrazzi M, Melloni E, Presta M.

J Immunol. 2006 Jan 1;176(1):12-5.

25.

Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4'-trimethoxystilbene.

Belleri M, Ribatti D, Nicoli S, Cotelli F, Forti L, Vannini V, Stivala LA, Presta M.

Mol Pharmacol. 2005 May;67(5):1451-9. Epub 2005 Feb 9.

26.

Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists.

Presta M, Oreste P, Zoppetti G, Belleri M, Tanghetti E, Leali D, Urbinati C, Bugatti A, Ronca R, Nicoli S, Moroni E, Stabile H, Camozzi M, Hernandez GA, Mitola S, Dell'Era P, Rusnati M, Ribatti D.

Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):71-6. Epub 2004 Oct 28.

27.

Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist.

Pisano C, Aulicino C, Vesci L, Casu B, Naggi A, Torri G, Ribatti D, Belleri M, Rusnati M, Presta M.

Glycobiology. 2005 Feb;15(2):1C-6C. Epub 2004 Oct 20.

PMID:
15496501
28.

Undersulfated and glycol-split heparins endowed with antiangiogenic activity.

Casu B, Guerrini M, Guglieri S, Naggi A, Perez M, Torri G, Cassinelli G, Ribatti D, Carminati P, Giannini G, Penco S, Pisano C, Belleri M, Rusnati M, Presta M.

J Med Chem. 2004 Feb 12;47(4):838-48.

PMID:
14761186
29.

Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors.

Casu B, Guerrini M, Naggi A, Perez M, Torri G, Ribatti D, Carminati P, Giannini G, Penco S, Pisano C, Belleri M, Rusnati M, Presta M.

Biochemistry. 2002 Aug 20;41(33):10519-28.

PMID:
12173939
30.

Anti-angiogenic activity of the purine analog 6-thioguanine.

Presta M, Belleri M, Vacca A, Ribatti D.

Leukemia. 2002 Aug;16(8):1490-9.

31.

Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils.

Scapini P, Nesi L, Morini M, Tanghetti E, Belleri M, Noonan D, Presta M, Albini A, Cassatella MA.

J Immunol. 2002 Jun 1;168(11):5798-804.

32.

Sinusoidal 50 Hz magnetic fields do not affect structural morphology and proliferation of human cells in vitro.

Supino R, Bottone MG, Pellicciari C, Caserini C, Bottiroli G, Belleri M, Veicsteinas A.

Histol Histopathol. 2001 Jul;16(3):719-26. doi: 10.14670/HH-16.719.

PMID:
11510961
33.

Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives.

Leali D, Belleri M, Urbinati C, Coltrini D, Oreste P, Zoppetti G, Ribatti D, Rusnati M, Presta M.

J Biol Chem. 2001 Oct 12;276(41):37900-8. Epub 2001 Jul 25.

34.

Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells.

Dell'Era P, Belleri M, Stabile H, Massardi ML, Ribatti D, Presta M.

Oncogene. 2001 May 10;20(21):2655-63.

35.

Alterations of blood vessel development by endothelial cells overexpressing fibroblast growth factor-2.

Ribatti D, Gualandris A, Belleri M, Massardi L, Nico B, Rusnati M, Dell'Era P, Vacca A, Roncali L, Presta M.

J Pathol. 1999 Dec;189(4):590-9.

PMID:
10629563
36.

Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process.

Presta M, Rusnati M, Belleri M, Morbidelli L, Ziche M, Ribatti D.

Cancer Res. 1999 May 15;59(10):2417-24.

37.

Noncompetitive, chemokine-mediated inhibition of basic fibroblast growth factor-induced endothelial cell proliferation.

Presta M, Belleri M, Vecchi A, Hesselgesser J, Mantovani A, Horuk R.

J Biol Chem. 1998 Apr 3;273(14):7911-9.

38.

Endothelial cells overexpressing basic fibroblast growth factor (FGF-2) induce vascular tumors in immunodeficient mice.

Sola F, Gualandris A, Belleri M, Giuliani R, Coltrini D, Bastaki M, Tosatti MP, Bonardi F, Vecchi A, Fioretti F, Ciomei M, Grandi M, Mantovani A, Presta M.

Angiogenesis. 1997;1(1):102-116.

PMID:
14517397
39.

Angiogenic phenotype induced by basic fibroblast growth factor transfection in brain microvascular endothelial cells.

Gualandris A, Rusnati M, Belleri M, Molinaritosatti M, Bonardi F, Albini A, Ziche M, Presta M.

Int J Oncol. 1996 Mar;8(3):567-73.

PMID:
21544398
40.

Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases.

Gualandris A, Rusnati M, Belleri M, Nelli EE, Bastaki M, Molinari-Tosatti MP, Bonardi F, Parolini S, Albini A, Morbidelli L, Ziche M, Corallini A, Possati L, Vacca A, Ribatti D, Presta M.

Cell Growth Differ. 1996 Feb;7(2):147-60.

41.

Development of chicken embryos exposed to an intermittent horizontal sinusoidal 50 Hz magnetic field.

Veicsteinas A, Belleri M, Cinquetti A, Parolini S, Barbato G, Molinari Tosatti MP.

Bioelectromagnetics. 1996;17(5):411-24.

PMID:
8915551
42.

Loss of muscle oxidative capacity after an extreme endurance run: the Paris-Dakar foot-race.

Höchli D, Schneiter T, Ferretti G, Howald H, Claassen H, Moia C, Atchou G, Belleri M, Veicsteinas A, Hoppeler H.

Int J Sports Med. 1995 Aug;16(6):343-6.

PMID:
7591382
43.

Heart rate overshoot at the beginning of muscle exercise.

Feroldi P, Belleri M, Ferretti G, Veicsteinas A.

Eur J Appl Physiol Occup Physiol. 1992;65(1):8-12.

PMID:
1505545
44.

[Cardiac effects of exhausting isometric muscular contraction in trained and endurance athletes].

Micheletti P, Macchi G, Finulli P, Belleri M.

G Ital Cardiol. 1990 Feb;20(2):148-57. Italian.

PMID:
2328869

Supplemental Content

Loading ...
Support Center